Mike Wheatcroft

Company: Telix Pharmaceuticals

Job title: Chief Scientist

Seminars:

Radioactive ADCs in Oncology & Autoimmune Diseases 3:30 pm

Radioimmunoconjugates are not a new class of drugs but improvements in conjugation technology, choices of isotopes and antibody engineering techniques has generated new interest Highlighting significant opportunities in both diagnostic and therapeutic medicine Outlining a number of recent late-stage developments in this exciting field, as well as potentially important new platform technologies for the futureRead more

day: Day One